NeoPharm CO., LTD. (KOSDAQ:092730)

Market Cap	268.56B +49.3%
Revenue (ttm)	132.18B +11.1%
Net Income	27.82B +20.6%
EPS	1,778.81 +20.6%
Shares Out	15.64M
PE Ratio	9.65
Forward PE	8.39
Dividend	750.00 (4.34%)
Ex-Dividend Date	Dec 29, 2025

Volume	47,562
Average Volume	45,198
Open	17,250
Previous Close	17,170
Day's Range	17,060 - 17,310
52-Week Range	12,370 - 22,650
Beta	0.57
RSI	45.25
Earnings Date	May 8, 2026

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2000
• Employees: 178
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092730

Financial Performance

In 2025, NeoPharm CO., LTD.'s revenue was 132.18 billion, an increase of 11.07% compared to the previous year's 119.01 billion. Earnings were 27.82 billion, an increase of 20.63%.